Shikonin reduces TGF-β1-induced collagen production and contraction in hypertrophic scar-derived human skin fibroblasts

Fan,Chen; Dong,Ying; Xie,Yan; Su,Yonghua; Zhang,Xufang; Leavesley,David; Upton,Zee

doi:10.3892/ijmm.2015.2299

Shikonin reduces TGF-β1-induced collagen production and contraction in hypertrophic scar-derived human skin fibroblasts

Authors:
- Chen Fan
- Ying Dong
- Yan Xie
- Yonghua Su
- Xufang Zhang
- David Leavesley
- Zee Upton
View Affiliations

Affiliations: Tissue Repair and Regeneration Program, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland 4059, Australia, Cancer Research Program, Translational Research Institute, Queensland University of Technology, Brisbane, Queensland 4102, Australia, Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China
Published online on: July 31, 2015 https://doi.org/10.3892/ijmm.2015.2299
Pages: 985-991
Copyright: © Fan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hypertrophic scarring/hypertrophic scars (HS) is a highly prevalent condition following burns and trauma wounds. Numerous studies have demonstrated that transforming growth factor-β1 (TGF‑β1) plays an essential role in the wound healing process by regulating cell differentiation, collagen production and extracellular matrix degradation. The increased expression of TGF-β1 is believed to result in the formation of HS. Shikonin (SHI), an active component extracted from the Chinese herb, Radix Arnebiae, has previously been found to downregulate the expression of TGF-β1 in keratinocyte/fibroblast co-culture conditioned medium. In view of this, in this study, we aimed to further investigate the effects of SHI on TGF-β1-stimulated hypertrophic scar-derived human skin fibroblasts (HSFs) and examined the underlying mechanisms. Cell viability and proliferation were measured using alamarBlue and CyQUANT assays. The total amount of collagen and cell contraction were examined using Sirius red staining and the cell contraction assay kit. Gene expression and signalling pathway activation were detected using reverse transcription-quantitative polymerase chain reaction and western blot analysis. Our results revealed that SHI reduced TGF-β1‑induced collagen production through the ERK/Smad signalling pathway and attenuated TGF-β1‑induced cell contraction by downregulating α-smooth muscle actin (αSMA) expression in the HSFs. The data from this study provide evidence supporting the potential use of SHI as a novel treatment for HS.

View Figures

View References

1	Aarabi S, Longaker MT and Gurtner GC: Hypertrophic scar formation following burns and trauma: New approaches to treatment. PLoS Med. 4:e2342007. View Article : Google Scholar : PubMed/NCBI
2	Xiao Z, Zhang M, Liu Y and Ren L: Botulinum toxin type a inhibits connective tissue growth factor expression in fibroblasts derived from hypertrophic scar. Aesthetic Plast Surg. 35:802–807. 2011. View Article : Google Scholar : PubMed/NCBI
3	Sun Z, Li S, Cao C, Wu J, Ma B and Tran V: shRNA targeting SFRP2 promotes the apoptosis of hypertrophic scar fibroblast. Mol Cell Biochem. 352:25–33. 2011. View Article : Google Scholar : PubMed/NCBI
4	Liu XJ, Xu MJ, Fan ST, Wu Z, Li J, Yang XM, Wang YH, Xu J and Zhang ZG: Xiamenmycin attenuates hypertrophic scars by suppressing local inflammation and the effects of mechanical stress. J Invest Dermatol. 133:1351–1360. 2013. View Article : Google Scholar : PubMed/NCBI
5	Huang D, Shen KH and Wang HG: Pressure therapy upregulates matrix metalloproteinase expression and downregulates collagen expression in hypertrophic scar tissue. Chin Med J (Engl). 126:3321–3324. 2013.
6	Gauglitz GG, Korting HC, Pavicic T, Ruzicka T and Jeschke MG: Hypertrophic scarring and keloids: Pathomechanisms and current and emerging treatment strategies. Mol Med. 17:113–125. 2011. View Article : Google Scholar :
7	Liu BH, Chen L, Li SR, Wang ZX and Cheng WG: Smac/DIABLO regulates the apoptosis of hypertrophic scar fibroblasts. Int J Mol Med. 32:615–622. 2013.PubMed/NCBI
8	Simon F, Bergeron D, Larochelle S, Lopez-Vallé CA, Genest H, Armour A and Moulin VJ: Enhanced secretion of TIMP-1 by human hypertrophic scar keratinocytes could contribute to fibrosis. Burns. 38:421–427. 2012. View Article : Google Scholar
9	Yin L, Zhao X, Ji S, He C, Wang G, Tang C, Gu S and Yin C: The use of gene activated matrix to mediate effective SMAD2 gene silencing against hypertrophic scar. Biomaterials. 35:2488–2498. 2014. View Article : Google Scholar : PubMed/NCBI
10	Liu S, Jiang L, Li H, Shi H, Luo H, Zhang Y, Yu C and Jin Y: Mesenchymal stem cells prevent hypertrophic scar formation via inflammatory regulation when undergoing apoptosis. J Invest Dermatol. 134:2648–2657. 2014. View Article : Google Scholar : PubMed/NCBI
11	Wang R, Ghahary A, Shen Q, Scott PG, Roy K and Tredget EE: Hypertrophic scar tissues and fibroblasts produce more transforming growth factor-beta1 mRNA and protein than normal skin and cells. Wound Repair Regen. 8:128–137. 2000. View Article : Google Scholar : PubMed/NCBI
12	Ehrlich HP, Desmoulière A, Diegelmann RF, Cohen IK, Compton CC, Garner WL, Kapanci Y and Gabbiani G: Morphological and immunochemical differences between keloid and hypertrophic scar. Am J Pathol. 145:105–113. 1994.PubMed/NCBI
13	Varga J and Abraham D: Systemic sclerosis: A prototypic multi-system fibrotic disorder. J Clin Invest. 117:557–567. 2007. View Article : Google Scholar : PubMed/NCBI
14	Colwell AS, Phan TT, Kong W, Longaker MT and Lorenz PH: Hypertrophic scar fibroblasts have increased connective tissue growth factor expression after transforming growth factor-beta stimulation. Plast Reconstr Surg. 116:1387–1392. 2005. View Article : Google Scholar : PubMed/NCBI
15	Chen X, Yang L, Oppenheim JJ and Howard MZ: Cellular pharmacology studies of shikonin derivatives. Phytother Res. 16:199–209. 2002. View Article : Google Scholar : PubMed/NCBI
16	Jones LJ, Gray M, Yue ST, Haugland RP and Singer VL: Sensitive determination of cell number using the CyQUANT cell proliferation assay. J Immunol Methods. 254:85–98. 2001. View Article : Google Scholar : PubMed/NCBI
17	Malkusch W, Rehn B and Bruch J: Advantages of Sirius Red staining for quantitative morphometric collagen measurements in lungs. Exp Lung Res. 21:67–77. 1995. View Article : Google Scholar : PubMed/NCBI
18	Singer AJ and Clark RA: Cutaneous wound healing. N Engl J Med. 341:738–746. 1999. View Article : Google Scholar : PubMed/NCBI
19	Urioste SS, Arndt KA and Dover JS: Keloids and hypertrophic scars: Review and treatment strategies. Semin Cutan Med Surg. 18:159–171. 1999. View Article : Google Scholar : PubMed/NCBI
20	Piek E, Moustakas A, Kurisaki A, Heldin CH and ten Dijke P: TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci. 112:4557–4568. 1999.PubMed/NCBI
21	Wrana JL and Attisano L: The Smad pathway. Cytokine Growth Factor Rev. 11:5–13. 2000. View Article : Google Scholar : PubMed/NCBI
22	Massague J: Integration of Smad and MAPK pathways: A link and a linker revisited. Genes Dev. 17:2993–2997. 2003. View Article : Google Scholar
23	Inman GJ: Linking Smads and transcriptional activation. Biochem J. 386:e1–e3. 2005. View Article : Google Scholar : PubMed/NCBI
24	Hough C, Radu M and Doré JJ: Tgf-beta induced Erk phosphorylation of smad linker region regulates smad signaling. PLoS One. 7:e425132012. View Article : Google Scholar : PubMed/NCBI
25	Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
26	Li J, Zhao Z, Liu J, Huang N, Long D, Wang J, Li X and Liu Y: MEK/ERK and p38 MAPK regulate chondrogenesis of rat bone marrow mesenchymal stem cells through delicate interaction with TGF-beta1/Smads pathway. Cell Prolif. 43:333–343. 2010. View Article : Google Scholar : PubMed/NCBI
27	Darby IA and Hewitson TD: Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol. 257:143–179. 2007. View Article : Google Scholar : PubMed/NCBI
28	Zhang Z, Garron TM, Li XJ, Liu Y, Zhang X, Li YY and Xu WS: Recombinant human decorin inhibits TGF-β1-induced contraction of collagen lattice by hypertrophic scar fibroblasts. Burns. 35:527–537. 2009. View Article : Google Scholar : PubMed/NCBI
29	Franz M, Spiegel K, Umbreit C, Richter P, Codina-Canet C, Berndt A, Altendorf-Hofmann A, Koscielny S, Hyckel P, Kosmehl H, et al: Expression of Snail is associated with myofibroblast phenotype development in oral squamous cell carcinoma. Histochem Cell Biol. 131:651–660. 2009. View Article : Google Scholar : PubMed/NCBI
30	Ibrahim MM, Bond J, Bergeron A, Miller KJ, Ehanire T, Quiles C, Lorden ER, Medina MA, Fisher M, Klitzman B, et al: A novel immune competent murine hypertrophic scar contracture model: A tool to elucidate disease mechanism and develop new therapies. Wound Repair Regen. 22:755–764. 2014. View Article : Google Scholar : PubMed/NCBI
31	Wang J, Dodd C, Shankowsky HA, Scott PG and Tredget EE; Wound Healing Research Group: Deep dermal fibroblasts contribute to hypertrophic scarring. Lab Invest. 88:1278–1290. 2008. View Article : Google Scholar : PubMed/NCBI